[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573998":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":55,"collaborators":26,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"German University in Cairo","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"l-carnitine and conventional DMARDs","EXPERIMENTAL","l-carnitine 500 mg ( carnitine tartrate 500 mg) two capsules twice daily for three months as add on therapy to conventional DMARDs.",[13,14],"Drug: Carnitine","Drug: Disease-modifying anti-rheumatic drugs",{"label":16,"type":17,"description":18,"interventionNames":19},"placebo and conventional DMARDs","PLACEBO_COMPARATOR","placebo 500 mg two capsules twice daily for three months as add on therapy to conventional DMARDs.",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Carnitine","It is a nutritional supplement with trade name \" Carnitol®\" in Egypt.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Disease-modifying anti-rheumatic drugs","They are immunosuppressive drugs used to improve disease activity in Rheumatoid Arthritis patients . Conventional DMARDs include methotrexate (Imutrexate®) , leflunomide(Arthfree®) , hydroxychloroquine (plaquenil®) and sulfasalazine(colosalazine®) .",[9,16],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Mariam Ehab, Master","CONTACT","+2001223360548","mariam.ehab-azmy@guc.edu.eg",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":26,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Demerdash hospital","RECRUITING","Cairo","Demerdash","Egypt","EG",{"type":46,"coordinates":47},"Point",[48,49],31.24967,30.06263,{"lat":49,"lon":48},[52],{"name":53,"role":34,"phone":54,"phoneExt":26,"email":26},"Amr Hawwash, PhD","+2001123902218",{"type":56,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100573998","phase-2-l-carnitine-supplementation-in-rheumatoid-arthritis-patients-100573998",false,"NCT06753565","L-carnitine Supplementation in Rheumatoid Arthritis Patients","Effect of L-carnitine Supplementation on Disease Activity in Rheumatoid Arthritis Patients","Inclusion Criteria:\n\n* age between 18-60 years old\n* diagnosed of rheumatoid arthritis according to 2010 American College of Rheumatology\u002FEuropean League Against Rheumatism criteria for at least 6 months\n* enrolled patients treated with one of more of conventional DMARDs for ≥ 6 months with stable dose for ≥ 1 month before start of the study\n* active RA despite conventional DMARDs treatment (DAS28 ESR more than or equal 3.2)\n* patient or legal representative should sign informed consent\n\nExclusion Criteria:\n\n* pregnant or lactating female\n* patients with liver dysfunction (\\>1.5x the upper limit of normal value for ALT \\& AST)\n* Patients with kidney dysfunction (serum creatinine more than 1.2 mg\u002Fdl)\n* Patients with any active infection or concurrent malignancy\n* patients with uncontrolled medical conditions or other rheumatic diseases\n* patients currently taking drugs that could interact with carnitine like: warfarin","ALL","18 Years","60 Years",{"count":68,"type":69},60,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","This study aims to evaluate the effect of l-carnitine as add- on therapy for improving the outcome in rheumatoid arthritis patients.",[75],"Rheumatoid Arthritis (RA)",[77,23,78,79,80,81],"Rheumatoid Arthritis","anti-inflammatory","anti-oxidant","ACR50%","disease activity","2025-01-04",{"date":84,"type":85},"2025-01-07","ACTUAL",{"date":87,"type":85},"2024-12-31",{"date":89,"type":69},"2025-06",{"name":5,"class":6},1]